Comparative Pharmacology
Head-to-head clinical analysis: ABILIFY MAINTENA KIT versus ABILIFY MYCITE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABILIFY MAINTENA KIT versus ABILIFY MYCITE KIT.
ABILIFY MAINTENA KIT vs ABILIFY MYCITE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The MyCite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
None Documented
None Documented
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Category C
Category C
Atypical antipsychotic
Atypical antipsychotic